CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
CRISPR Therapeutics' stock is down 20% since March, with ongoing high cash burn despite a robust $1.86 billion cash position. Casgevy's commercialization is slow, with over 65 treatment centers active but no recognized revenue yet, reflecting a complex administration process and gradual gene therapy adoption. Regulatory uncertainties under Dr. Vinay Prasad's FDA leadership could delay approvals, impacting CRISPR's gene and cell therapy timelines.
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago.
CRISPR Therapeutics (CRSP) Short Sellers Have A Lot Riding on Earnings
Shares of CRISPR Therapeutics (NASDAQ:CRSP) can't seem to catch a break, now down close to 8% year to date and more than 80% from now-distant 2021 all-time highs.
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better positioned to navigate near-term challenges with a strong cash reserve and upcoming product launches, justifying an upgrade to 'Strong Buy.' NTLA, despite promising product candidates, faces higher risks and requires significant cost reductions to extend its cash runway, maintaining a "Buy" rating for high-risk investors.
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.25, moving +1.38% from the previous trading session.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
2 Beaten-Down Stocks With Incredible Upside Potential
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day.
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $38.54, denoting a -1.76% change from the preceding trading day.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.
